Human Papillomavirus Infection

"In 2006, Health Canada approved the first vaccine to prevent Human Papillomavirus (HPV) infection (Gardasil, Merck Frosst Canada Ltd). Gardasil® is a highly effective quadrivalent HPV vaccine targeting highrisk HPV subtypes 16 and 18 as well as low-risk HPV subtypes 6 and 11 . The National Advisory Committee on Immunization (NACI) released a statement in 2007 with the recommendation to vaccinate girls between 9 and 13 years of age for the prevention of infection caused by the HPV subtypes 6, 11, 16, and 18 and their associated diseases like cervical cancer, vulvar and vaginal cancers, genital warts (Condyloma Acuminata, Cervical Adenocarcinoma In Situ (AIS), Cervical Intraepithelial Neoplasia (CIN) grades 1, 2 and 3, vulvar and Vaginal Intraepithelial Neoplasia (VIN) grades 2 and 3. In February 2010, Gardasil® was authorized to expand its indications to include males 9 to 26 years of age for the prevention of infection caused by HPV subtypes 6, 11, 16, and 18. In April 2011, Gardasil® was approved for use in women up to the age of 45 years. Since then, HPV vaccination programs have become widespread in Canada. On May of 2008, Manitoba has announced the introduction of a HPV immunization program whereby every grade six girl will be vaccinated with Gardasil, provided consent from her parent or legal guardian is obtained . (Wadi KAl, Poliquin V, Poliquin G, Lotocki R, Avery L (2014) The Perceived Role of Physicians with Regard to the Human Papillomavirus Vaccine.)"

• Share this page
• 
• 
• 
• 
• 
• 

Last date updated on April, 2024